In addition to clinical trials investigating the efficacy of MTDIA alone in cancer mouse models that have effectively been treated with MTDIA (Basu et al., 2007, 2011; Firestone et al., 2021), our results indicate that a synthetic lethal approach is also effective (e.g. synergy of MTDIA and rapamycin), particularly with 15% of all cancers being classified as ‘MTAP cancers’, i.e. as cancers comprising upregulated levels of MTAP. The gene discussed is MTAP; the disease is cancer.